A substantial drop in prescription drug user fee revenue last year, suspected to have been caused by delayed application submissions, forced the US Food and Drug Administration to scale back user-fee-related capacity planning.
The agency suggested in a 25 February notice to government contractors that the “unexpected and large drop in collections”...








